RxDoctor Payments Data

Michael Spearman, MD

Internal Medicine · Overland, MONPI 1164598579

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 47 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$347
  • AstraZeneca$267
  • Novo Nordisk$214
  • Pfizer$187
  • Exact Sciences$61
  • AbbVie$43
  • plus $49 from 2 others

What the payments were for

  • Food & beverage$1,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC12$347
AstraZeneca3$267
Novo Nordisk7$214
Pfizer17$187
Exact Sciences3$61
AbbVie2$43
Gilead2$32
Johnson & Johnson1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$1,259
Medicare patients
36
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$67,836
TrulicityDulaglutide45$62,457
OzempicSemaglutide44$55,731
Spiriva HandihalerTiotropium Bromide48$51,258
FarxigaDapagliflozin Propanediol35$42,723
EliquisApixaban38$36,465
XareltoRivaroxaban24$28,437
EntrestoSacubitril/Valsartan15$18,694
SymbicortBudesonide/Formoterol Fumarate49$15,248
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$4,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,109
Albuterol Sulfate HfaAlbuterol Sulfate143$4,033
Varenicline Tartrate17$3,832
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,480
Humalog Kwikpen U-100Insulin Lispro15$3,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$347$62,45745 claims
AstraZenecaFarxiga, Symbicort$267$57,97184 claims
Novo NordiskOzempic$214$55,73144 claims
PfizerEliquis$187$36,46538 claims
Johnson & JohnsonXarelto$17$28,43724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Overland

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →